ArticleCureus2025
Beyond Effectiveness: Impact of Cladribine on Patient-Reported Outcomes and Quality of Life in Latin American Populations With Multiple Sclerosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis multicenter, prospective, observational study evaluated the real-world effectiveness, safety, and impact on patient-reported outcomes (PROs) and functionality of cladribine (CLAD) in 167 relapsing multiple sclerosis (RMS) patients from Chile, Mexico, Argentina, and Ecuador between 2019 and 2024.
methodsPatients were assessed for clinical relapses, magnetic resonance imaging (MRI) activity, and disability progression. A subgroup underwent additional cognitive, motor, and PRO evaluations.
resultsThe annualized relapse rate (ARR) significantly decreased from 0.65 ± 0.6 pre-treatment to 0.12 ± 0.4 in year one, 0.08 ± 0.3 in year two, 0.06 ± 0.3 in year three, and 0.15 ± 0.5 in year four. No evidence of disease activity-3 (NEDA-3) was achieved by 68% (n = 100/147), 77% (n = 89/115), 86% (n = 61/71), and 82% (n = 37/45) of patients in years one, two, three, and four, respectively. Common adverse events were mild infections and lymphopenia (grade I 33% n = 48, grade II 30% n = 44, grade III 8% n = 12, and grade IV 0.01% n = 1 in year one). No treatment delays occurred due to lymphopenia. Two patients had healthy newborns after becoming pregnant between CLAD courses. Significant improvements were observed in visual memory, verbal memory, and anxiety levels at two years.
conclusionCLAD demonstrates an effectiveness and safety profile consistent with clinical trials in Latin American RMS populations, also improving PROs and functional outcomes, supporting its use as a viable treatment option.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.